Esperite Overview

  • Year Founded
  • 2000

Year Founded

  • Status
  • Public

  • Employees
  • 72

Employees

  • Investments
  • 5

  • Share Price
  • $5.54
  • (As of Wednesday Closing)

Esperite General Information

Description

Operator of a healthcare company intended for innovative medical advancements. The company's operations include extracting and storing adult human stem cells, research and development for therapeutic applications, predictive medicine insights, and other specialized services, enabling patients and healthcare providers to access technologies for stem cell preservation, genetic diagnostics, and personalized treatment strategies.

Contact Information

Website
www.esperite.com
Formerly Known As
Cryo-Save Group
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Herengracht 282
  • 1016 BX Amsterdam
  • Netherlands
Primary Industry
Biotechnology
Other Industries
Other Pharmaceuticals and Biotechnology
Other Healthcare Services
Vertical(s)
Life Sciences
Corporate Office
  • Herengracht 282
  • 1016 BX Amsterdam
  • Netherlands

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Esperite Stock Performance

As of 25-Jan-2012, Esperite’s stock price is $5.54. Its current market cap is $55.3M.

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.54 $5.15 $5.08 - $7.19 $55.3M 715.12 $0.35

Esperite Financials Summary

As of 31-Dec-2018, Esperite has a trailing 12-month revenue of $14M.

In Thousands,
USD 		TTM 31-Dec-2018 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017 FY 2016 31-Dec-2016
Revenue 13,973 13,973 18,668 29,041
EBITDA (18,565) (18,565) (7,351) (7,329)
Net Income (21,806) (21,806) (14,347) (9,299)
Total Assets 12,830 12,830 40,650 44,676
Total Debt 12,565 12,565 7,342 5,862
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Esperite Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Esperite‘s full profile, request access.

Request a free trial

Esperite Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Esperite Investments & Acquisitions (5)

Esperite’s most recent deal was a Merger/Acquisition with Cryo-Save South Africa. The deal was made on 16-May-2018.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Cryo-Save South Africa 16-May-2018 Merger/Acquisition Laboratory Services (Healthcare)
InKaryo 19-Mar-2015 Merger/Acquisition Outcome Management (Healthcare)
Cryo-Save South Africa 01-Apr-2013 Joint Venture Laboratory Services (Healthcare)
Salus Futura 14-Jul-2009 Merger/Acquisition Biotechnology
Output Pharma Services 01-Jan-2008 Merger/Acquisition Logistics
To view Esperite’s complete investments and acquisitions history, request access »

Esperite Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Cryo-Save South Africa Pretoria, South Africa 2013

Esperite FAQs

  • When was Esperite founded?

    Esperite was founded in 2000.

  • Where is Esperite headquartered?

    Esperite is headquartered in Amsterdam, Netherlands.

  • What is the size of Esperite?

    Esperite has 72 total employees.

  • What industry is Esperite in?

    Esperite’s primary industry is Biotechnology.

  • Is Esperite a private or public company?

    Esperite is a Public company.

  • What is the current stock price of Esperite?

    As of 25-Jan-2012 the stock price of Esperite is $5.54.

  • What is the current market cap of Esperite?

    The current market capitalization of Esperite is $55.3M.

  • What is Esperite’s current revenue?

    The trailing twelve month revenue for Esperite is $14M.

  • What is Esperite’s annual earnings per share (EPS)?

    Esperite’s EPS for 12 months was $0.35.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »